الرئيسية » أخبار (صفحة 4)

أخبار

Bluebird puts €1.58m price on gene therapy Zynteglo

  Bluebird bio Inc. set a price for its gene therapy, Zynteglo, at 1.58 million euros ($1.78 million) over five years, after winning conditional approval in Europe earlier this month to to treat patients 12 years and older with transfusion-dependent β-thalassaemia (TDT), who have no matching donor for a stem ...

أكمل القراءة »

A milestone in the treatment of b-thalassaemia – The 1st gene therapy for Transfusion Dependent β-Thalassaemia wins approval in Europe

  Zynteglo, Bluebird Bio’s ex vivo gene therapy for β-thalassaemia, got a green light from the EMA for conditional marketing authorization making it the 1st gene therapy for patients with thalassaemia to win such an approval.  The one-time gene therapy has been approved for patients 12 years and older with ...

أكمل القراءة »

Gene Therapy and Thalassaemia: The Patients’ Perspective survey!

  A significant number of gene therapy approaches are currently undergoing clinical trials, some of which are already producing encouraging results. The Bluebird Bio’s gene therapy product, under the name ZYNTEGLO™, has received positive comments from the scientific committees of the European drug regulatory authority (EMA). This means that the practical ...

أكمل القراءة »

Living with Transfusion-Dependent β-Thalassaemia (TDT)

In its most severe form and without adequate care, thalassaemia can be lethal in early childhood, and although  International Thalassaemia Day has come and gone, awareness is paramount.   Andrew Obenshain, Head of Europe at gene therapy company bluebird bio, looks into what it means to live with thalassaemia, with ...

أكمل القراءة »